Expanding the spectrum of pathogens in urethritis: Implications for presumptive therapy?

Clinical Infectious Diseases

Volumn 45, Issue 7, 2007, Pages 872-874

  Manhart, Lisa E ^a   Golden, Matthew R ^a   Marrazzo, Jeanne M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN; DOXYCYCLINE; GATIFLOXACIN; MOXIFLOXACIN; RIFALAZIL; SPECTINOMYCIN; TETRACYCLINE;

ABSTINENCE; ANTIBIOTIC SENSITIVITY; CHLAMYDIA TRACHOMATIS; GLUCOSE BLOOD LEVEL; GONOCOCCAL URETHRITIS; HUMAN; MYCOPLASMA GENITALIUM; NEISSERIA GONORRHOEAE; NOTE; PREVALENCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; UNITED STATES; UREAPLASMA UREALYTICUM; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CHLAMYDIASIS; DRUG EFFECT; GONORRHEA; GRAM NEGATIVE INFECTION; MALE; METHODOLOGY; MICROBIOLOGY; URETHRITIS;

ANTIBIOTIC PROPHYLAXIS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; GONORRHEA; HUMANS; MALE; MYCOPLASMA GENITALIUM; MYCOPLASMA INFECTIONS; UREAPLASMA INFECTIONS; UREAPLASMA UREALYTICUM; URETHRITIS;

EID: 34848886363     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521265     Document Type: Note

References (32)

1. Morton RS. Gonorrhoea. In: Major problems in dermatology. Vol. 9. London: W. B. Saunders, 1977.
2. Sparling PF. Biology of Neisseria gonorrhoeae. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually transmitted diseases. 3rd ed. New York: McGraw Hill, 1999:433-50.
3. Centers for Disease Control and Prevention. Increases in gonorrhea - eight western states, 2000-2005. MMWR Morb Mortal Wkly Rep 2007; 56:222-5.
4. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332-6.
5. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2005. Atlanta, GA: U.S. Department of Health and Human Services, 2006.
6. Oriel JD, Ridgway GL, Tchamouroff S, Owen J. Spectinomycin hydrochloride in the treatment of gonorrhoea: its effect on associated Chlamydia trachomatis infections. Br J Vener Dis 1977; 53:226-9.
7. Bowie WR, Alexander ER, Holmes KK. Etiologies of postgonococcal urethritis in homosexual and heterosexual men: roles of Chlamydia trachomatis and Ureaplasma urealyticum. Sex Transm Dis 1978; 5:151-4.
8. Kinghorn GR. Postgonococcal urethritis: relationship to penicillin sensitivity of the gonococcus. Br J Vener Dis 1978; 54:112-4.
9. Terho P. Chlamydia trachomatis in gonococcal and postgonococcal urethritis. Br J Vener Dis 1978; 54:326-9.
10. Jensen JS. Mycoplasma genitalium: the aetiological agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol 2004; 18:1-11.
11. Deguchi T, Yoshida T, Miyazawa T, et al. Association of Ureaplasma urealyticum (biovar 2) with nongonococcal urethritis. Sex Transm Dis 2004; 31:192-5.
12. Povlsen K, Björnelius E, Lidbrink P, Lind I. Relationship of Ureaplasma urealyticum biovar 2 to nongonococcal urethritis. Eur J Clin Microbiol Infect Dis 2002; 21:97-101.
13. Bradshaw CS, Tabrizi SN, Read TRH, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006; 193:336-45.
14. Yokoi S, Maeda S, Kubota Y, et al. The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal urethritis. Clin Infect Dis 2007; 45:866-71 (in this issue).
15. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. Atlanta, GA: Division of STD Prevention, 2006.
16. World Health Organization (WHO). Guidelines for the management of sexually transmitted infections. Geneva: WHO, 2003.
17. Johannisson G, Enstrom Y, Lowhagen GB, et al. Occurrence and treatment of Mycoplasma genitalium in patients visiting STD clinics in Sweden. Int J STD AIDS 2000; 11:324-6.
18. Falk L, Fredlund H, Jensen JS. Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex Transm Infect 2003; 79:318-9.
19. Björnelius E, Anagrius C, Goys G, et al. Mycoplasma genitalium: when to test and treat: present status in Scandinavia [abstract 0388]. In: Program and abstracts of the 15th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research (Ottawa, Canada). 2003:137.
20. Mroczkowski TF, Mena LA, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium (MG) positive urethritis in men (abstract WP-107). In: Program and abstracts of the 16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research (Amsterdam). 2005:304.
21. Gambini D, Decleva I, Lupica L, Ghislanzoni M, Cusini M, Alessi E. Mycoplasma genitalium in males with nongonococcal urethritis: prevalence and clinical efficacy of eradication. Sex Transm Dis 2000; 27:226-9.
22. Bradshaw CS, Jensen JS, Tabrizi SN, et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12:1149-52.
23. Yasuda M, Maeda S, Deguchi T. In vitro activity of fluoroquinolones against Mycoplasma genitalium and their bacteriological efficacy for treatment of M. genitalium-positive nongonococcal urethritis in men. Clin Infect Dis 2005; 41:1357-9.
24. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-61.
25. Stamm WE, Batteiger BE, McCormack WM, Totten PA, Sternlicht A, Kivel NM. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. Sex Transm Dis 2007 [epub ahead of print].
26. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995; 274:545-9.
27. Skerk V, Marekovic I, Markovinovic L, et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum. Chemotherapy 2005; 52:9-11.
28. Romanowski B, Talbot H, Stadnyk M, Kowalchuk P, Bowie WR. Minocycline compared with doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Ann Intern Med 1993; 119:16-22.
29. Bowie WR, Yu JS, Fawcett A, Jones HD. Tetracycline in nongonococcal urethritis: comparison of 2 g and 1g daily for seven days. Br J Vener Dis 1980; 56:332-6.
30. Abele-Horn M, Wolff C, Dressel P, Pfaff F, Zimmermann A. Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease. J Clin Microbiol 1997; 35:1199-202.
31. Domingues D, Tavira LT, Duarte A, Sanca A, Prieto E, Exposto F. Ureaplasma urealyticum biovar determination in women attending a family planning clinic in Guine-Bissau, using polymerase chain reaction of the multiple-banded antigen gene. J Clin Lab Anal 2002; 16:71-5.
32. Martinez MA, Ovalle A, Santa-Cruz A, Barrera B, Vidal R, Aguirre R. Occurrence and antimicrobial susceptibility of Ureaplasma parvum (Ureaplasma urealyticum biovar 1) and Ureaplasma urealyticum (Ureaplasma urealyticum biovar 2) from patients with adverse pregnancy outcomes and normal pregnant women. Scand J Infect Dis 2001; 33:604-10.